Sandoz Pty Ltd. Sandoz

Sandoz Pty Ltd. Sandoz is an Australian private company specializing in the importation and distribution of finished pharmaceutical formulations. Established on October 23, 1996, and registered for Goods and Services Tax (GST) since July 1, 2000, the company operates under the Australian Business Number (ABN) 60 075 449 553 and the Australian Company Number (ACN) 075 449 553. Headquartered in North Sydney, New South Wales, Sandoz Pty Ltd. Sandoz is a subsidiary of Sandoz Group AG, a global leader in generic pharmaceuticals and biosimilars headquartered in Basel, Switzerland.

In Australia, Sandoz Pty Ltd. Sandoz plays a pivotal role in enhancing access to affordable, high-quality medicines. The company imports a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, thereby contributing significantly to the pharmaceutical supply chain. By leveraging its global network and expertise, Sandoz Pty Ltd. Sandoz ensures a steady supply of essential medications to meet the needs of healthcare providers and patients across Australia.

Sandoz Pty Ltd. Sandoz maintains a robust distribution network within Australia, with its headquarters situated in North Sydney, New South Wales. While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic positioning in North Sydney suggests proximity to major transportation hubs, facilitating efficient distribution across the country. This central location enables Sandoz Pty Ltd. Sandoz to effectively manage its supply chain and ensure timely delivery of pharmaceutical products to various regions within Australia.

Sandoz Pty Ltd. Sandoz operates as a pharmaceutical importer and distributor within Australia's supply chain. By importing finished pharmaceutical formulations from international suppliers, the company enhances the availability of essential medications in the Australian market. Its role is crucial in bridging the gap between global pharmaceutical manufacturers and local healthcare providers, ensuring that patients have access to a wide array of therapeutic options.

Sandoz Pty Ltd. Sandoz demonstrates a high degree of supplier concentration, sourcing all its imported pharmaceutical formulations from a single supplier, CIPLA LIMITED. This exclusive sourcing strategy indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply. However, this dependency also introduces risks; any disruptions in CIPLA LIMITED's production or supply chain could directly impact Sandoz Pty Ltd. Sandoz's ability to meet market demand. The company's shipment data, comprising 20 shipments valued at $1.0 million USD, reflects a stable and ongoing relationship with CIPLA LIMITED, suggesting effective collaboration and mutual trust.

The resilience of Sandoz Pty Ltd. Sandoz's supply chain is closely tied to its exclusive relationship with CIPLA LIMITED. While this partnership may offer advantages in terms of product consistency and supply reliability, it also exposes the company to potential risks associated with single-source dependency. The absence of backup suppliers and limited formulation diversity could pose challenges in the event of supply disruptions. Additionally, the company's reliance on a single supplier may limit its ability to adapt to changing market demands or regulatory requirements. Ensuring the regulatory compliance of CIPLA LIMITED, particularly in adhering to Good Manufacturing Practice (GMP) standards, is essential to maintain the integrity and quality of the imported products.

Sandoz Pty Ltd. Sandoz's sourcing pattern, characterized by exclusive reliance on CIPLA LIMITED, positions the company to benefit from a streamlined supply chain and potentially favorable terms. However, this strategy also necessitates a thorough assessment of the associated risks, including supply chain vulnerabilities and the impact of any disruptions. For Indian exporters, this presents an opportunity to diversify their customer base by offering alternative products or formulations that align with Sandoz Pty Ltd. Sandoz's quality standards and regulatory requirements. Establishing a relationship with Sandoz Pty Ltd. Sandoz could lead to increased market penetration in Australia, provided that the exporters can meet the company's specific needs and expectations.

In Australia, the Therapeutic Goods Administration (TGA) serves as the primary regulatory authority overseeing the importation, manufacture, and supply of therapeutic goods, including pharmaceuticals. The TGA operates under the Therapeutic Goods Act 1989, which establishes a national system to ensure the quality, safety, efficacy, and timely availability of therapeutic goods used in Australia. (tga.gov.au) This legislation is complemented by the Therapeutic Goods Regulations 1990, which provide detailed requirements related to the manufacturing, supply, and advertising of therapeutic goods. Additionally, the Poisons Standard, also known as the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP), classifies medicines and poisons into schedules, guiding their regulation and control.

Import licensing in Australia is governed by the Therapeutic Goods Administration (TGA), which requires that all therapeutic goods imported into the country be included in the Australian Register of Therapeutic Goods (ARTG). This inclusion ensures that the products meet the necessary quality, safety, and efficacy standards. Good Manufacturing Practice (GMP) certification is a critical component of the import licensing process. The TGA recognizes GMP certificates from various international standards, including those issued by the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications affirm that manufacturing processes adhere to internationally accepted quality standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of therapeutic goods, ensuring compliance with regulatory standards and the maintenance of product integrity throughout the supply chain.

Imported pharmaceutical products in Australia must undergo batch testing to verify their quality, safety, and efficacy. Stability requirements are also enforced to ensure that products maintain their intended quality throughout their shelf life. Labeling requirements stipulate that product information be provided in English, including details such as dosage instructions, active ingredients, and storage conditions. Serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market. These regulatory measures are designed to protect public health by ensuring that imported pharmaceutical products meet the necessary standards for use in Australia.

Between 2024 and 2026, several policy changes have impacted the importation of Indian pharmaceutical products into Australia. The Therapeutic Goods Legislation Amendment (2023 Measures No. 2) Regulations 2023, registered on November 27, 2023, introduced updates to the regulatory framework governing therapeutic goods. (tga.gov.au) These amendments may affect the importation processes, including requirements for product registration, labeling, and compliance with international standards. Additionally, the Therapeutic Goods Amendment (2022 Measures No. 1) Act 2023, passed on March 9, 2023, introduced further changes to the legislative framework, potentially influencing the importation and distribution of pharmaceutical products in Australia. (tga.gov.au)

Sandoz Pty Ltd. Sandoz's product strategy focuses on the importation of pharmaceutical formulations within the respiratory therapeutic category, specifically Fluticasone and Salmeterol. The company's total import value from India amounts to $1.0 million USD, with 20 shipments comprising 227 unique formulations. The exclusive sourcing of these products from CIPLA LIMITED suggests a strategic emphasis on ensuring consistent product quality and supply reliability. The choice to import these specific therapeutic products may be driven by market demand for respiratory treatments in Australia, as well as the availability and quality of these formulations from CIPLA LIMITED.

Sandoz Pty Ltd. Sandoz's sourcing strategy is characterized by a focus on generic pharmaceutical formulations, particularly within the respiratory therapeutic category. The company's exclusive reliance on CIPLA LIMITED for the importation of these products indicates a strategic partnership aimed at ensuring product consistency and supply chain efficiency. This sourcing approach aligns with Sandoz Pty Ltd. Sandoz's commitment to providing affordable, high-quality medicines to the Australian market.

Based on its product mix, Sandoz Pty Ltd. Sandoz primarily serves the Australian market by importing and distributing generic pharmaceutical formulations within the respiratory therapeutic category. The company's focus on Fluticasone and Salmeterol suggests a strategic positioning to meet the demand for respiratory treatments in Australia. By leveraging its exclusive sourcing relationship with CIPLA LIMITED, Sandoz Pty Ltd. Sandoz aims to provide consistent and reliable access to these essential medications for healthcare providers and patients across the country.

The exclusive sourcing arrangement between Sandoz Pty Ltd. Sandoz and CIPLA LIMITED presents both opportunities and challenges for potential new Indian suppliers. While the existing partnership may limit immediate opportunities for new entrants, there is potential for diversification within the respiratory therapeutic category or expansion into other therapeutic areas. New suppliers could explore offering alternative formulations or products that complement Sandoz Pty Ltd. Sandoz's existing portfolio,